|
|
|
|
Gamma delta T cells are emerging as a promising platform for cancer immunotherapy. In this webinar, we compare two clinical-scale expansion strategies that generate billions of highly functional gamma delta T cells, highlighting their potential for clinical-grade adoptive cell therapies.
|
|
|
|
|
Human serum has long been a critical component of CAR-T cell manufacturing, but its cost, variability, contamination risks, and limited supply present significant challenges for large-scale production. This poster introduces a chemically defined, serum-free medium that supports superior T-cell expansion and optimized culture practices.
|
|
|
|
|
Optimizing cytokine selection is essential for producing high-quality CAR-T cell therapies, and this study evaluates the performance of TheraPEAK AmpliCell Cytokines (IL-2, IL-7, and IL-15) against a leading competitor. The results in this application note demonstrate comparable cell expansion, viability, and CAR-T functionality.
|
|
|
|
|
Efficient and scalable delivery of CRISPR/Cas9 components is critical for advancing gene and cell therapies, and electroporation has emerged as the leading non-viral approach for clinical applications. Here, we demonstrate how the 4D-Nucleofector LV Unit PRO enables robust, scalable T-cell gene editing workflows.
|
|
|
|
|
|
|
Accelerate your cell and gene therapy journey with integrated technologies, GMP expertise, and end-to-end solutions designed to help bring transformative therapies to patients faster.
|
|
|
